Johnson & Johnson (BSP:JNJB34)
R$ 60.12 0 (0%) Market Cap: 2.18 Til Enterprise Value: 2.27 Til PE Ratio: 24.52 PB Ratio: 5.08 GF Score: 76/100

Johnson & Johnson at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2023 / 02:10PM GMT
Release Date Price: R$53.75 (-0.22%)
Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst

Thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley. And this morning, I'm very pleased to be hosting Johnson & Johnson. Today from the company, we have Joaquin Duato, who is the company's Chairman and CEO; and John Reed, who is Executive Vice President of Pharma, R&D. Thank you both so much for joining us. Really appreciate the time today.

Before we get started, for important disclosures, please see the Morgan Stanley Research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

Questions & Answers

Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst

Well, maybe I thought we'd get started, Joaquin, you've been in the role as CEO now for almost a year. And so maybe you could provide us an update kind of first on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot